An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemiaDavid A. Rizzieri, Gautam Borthakur, Kimberley Jackson et al.|Leukemia & lymphoma/Leukemia and lymphoma|2016Cited by 78